XML 66 R54.htm IDEA: XBRL DOCUMENT v3.19.2
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Feb. 28, 2017
USD ($)
Nov. 30, 2015
item
Feb. 28, 2015
Jan. 31, 2015
USD ($)
item
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Jun. 30, 2018
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
License agreements                            
Long term investment             $ 115,563     $ 115,563     $ 99,199  
Research and development expense             289,363   $ 298,089 559,908 $ 601,192      
Unrealized gain (loss) on long term investments             (4,625)   (34,641) 16,364 (11,962)      
Current assets             2,058,625     2,058,625     1,832,254  
Current liabilities             367,105     367,105     425,277  
Cash and cash equivalents             1,416,224     $ 1,416,224     1,163,980  
Agenus                            
License agreements                            
Number of program targets | item       3   4                
Royalty payments on future global net sales (as a percent)                   15.00%        
Upfront payment under license agreement           $ 60,000                
Period of notice for termination of license agreement     12 months                      
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                            
License agreements                            
Royalty payments on future global net sales (as a percent)                   6.00%        
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                            
License agreements                            
Royalty payments on future global net sales (as a percent)                   12.00%        
Additional milestone payments under the license agreement     $ 510,000                      
Agenus | Development Milestones                            
License agreements                            
Upfront payment under license agreement                       $ 20,000    
Additional milestone payments under the license agreement                 5,000   5,000     $ 5,000
Agenus                            
License agreements                            
Long term investment             53,300     $ 53,300     42,300  
Research and development expense             $ 500   900 $ 900 2,800      
Shares owned following stock purchase (as a percent)     11.00%   9.00%                  
Ownership percentage (as a percent)             16.00%     16.00%        
Unrealized gain (loss) on long term investments             $ 500   $ (43,300) $ 11,000 $ (17,600)      
Total revenues               $ 79,900            
Net income (loss)               $ 17,400            
Agenus | Accrued and other liabilities                            
License agreements                            
Accrued and other liabilities             $ 1,800     $ 1,800     $ 2,300  
Agenus | Stock purchase agreement                            
License agreements                            
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                        
Purchase price of common stock   $ 60,000                        
Per share price | $ / shares $ 4.40 $ 6.00                        
Discount for lack of marketability $ 4,500                          
Fair value of shares on the issuance date 39,500                          
Total consideration paid $ 60,000                          
Long term investment                       39,500    
Research and development expense                       $ 20,500